|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for FGFR1 |
 Gene summary |
| Basic gene Info. | Gene symbol | FGFR1 |
| Gene name | fibroblast growth factor receptor 1 | |
| Synonyms | BFGFR|CD331|CEK|FGFBR|FGFR-1|FLG|FLT-2|FLT2|HBGFR|HH2|HRTFDS|KAL2|N-SAM|OGD|bFGF-R-1 | |
| Cytomap | UCSC genome browser: 8p11.23-p11.22 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001174063.1, NM_001174064.1,NM_001174065.1,NM_001174066.1,NM_001174067.1, NM_015850.3,NM_023105.2,NM_023106.2,NM_023110.2, NM_023107.2,NM_023108.2,NM_023109.1,NM_023111.2, NM_032191.1, | |
| Description | FGFR1/PLAG1 fusionFMS-like tyrosine kinase 2basic fibroblast growth factor receptor 1fms-related tyrosine kinase 2heparin-binding growth factor receptorhydroxyaryl-protein kinaseproto-oncogene c-Fgr | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 136350 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000077782 | ||
| HPRD : 00634 | ||
| Vega : OTTHUMG00000147366 | ||
| Protein | UniProt: P11362 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_FGFR1 | |
| BioGPS: 2260 | ||
| Pathway | NCI Pathway Interaction Database: FGFR1 | |
| KEGG: FGFR1 | ||
| REACTOME: FGFR1 | ||
| Pathway Commons: FGFR1 | ||
| Context | iHOP: FGFR1 | |
| ligand binding site mutation search in PubMed: FGFR1 | ||
| UCL Cancer Institute: FGFR1 | ||
| Assigned class in mutLBSgeneDB | A: This gene has a literature evidence and it belongs to targetable_mutLBSgenes. | |
| References showing study about ligand binding site mutation for FGFR1. | 1. "Wilkie AO, Oldridge M, Tang Z, Maxson RE Jr. Craniosynostosis and related limb anomalies. Novartis Found Symp. 2001;232:122-33; discussion 133-43. Review. PubMed PMID: 11277076. " 11277076 2. "Zou L, Cao S, Kang N, Huebert RC, Shah VH. Fibronectin induces endothelial cell migration through β1 integrin and Src-dependent phosphorylation of fibroblast growth factor receptor-1 at tyrosines 653/654 and 766. J Biol Chem. 2012 Mar 2;287(10):7190-202. doi: 10.1074/jbc.M111.304972. Epub 2012 Jan 14. PubMed PMID: 22247553; PubMed Central PMCID: PMC3293564. " 22247553 3. "Ye X, Guilmatre A, Reva B, Peter I, Heuzé Y, Richtsmeier JT, Fox DJ, Goedken RJ, Jabs EW, Romitti PA. Mutation Screening of Candidate Genes in Patients with Nonsyndromic Sagittal Craniosynostosis. Plast Reconstr Surg. 2016 Mar;137(3):952-61. doi: 10.1097/01.prs.0000479978.75545.ee. PubMed PMID: 26910679; PubMed Central PMCID: PMC4770826. " 26910679 | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0008284 | positive regulation of cell proliferation | 8663044 | GO:0008543 | fibroblast growth factor receptor signaling pathway | 8663044 | GO:0010863 | positive regulation of phospholipase C activity | 18480409 | GO:0018108 | peptidyl-tyrosine phosphorylation | 18480409 | GO:0043406 | positive regulation of MAP kinase activity | 18480409 | GO:0046777 | protein autophosphorylation | 8622701 |
| Top |
| Ligand binding site mutations for FGFR1 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | R209 | A211V | BLCA | 1 | D218 | D218N | COAD | 1 | I545 | N546S | COAD | 1 | R209 | R209H | HNSC | 1 | L630,N628 | V629L | KIRC | 1 | K172 | A170S | LUAD | 1 | S565 | S565F | SKCM | 1 | I545 | N546D | STAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for FGFR1 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | R209 | R209H | -1.5058374 | S565 | S565F | -1.0308642 | D218 | D218N | -1.0272172 | I545 | N546D | -0.78314841 | I545 | N546S | -0.75995137 | N628 | V629L | -0.70924715 | L630 | V629L | -0.70924715 | R209 | A211V | -0.66475085 | K172 | A170S | -0.50802027 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for FGFR1 from PDB |
| Top |
| Differential gene expression and gene-gene network for FGFR1 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for FGFR1 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0162809 | Kallmann Syndrome | 36 | Biomarker, GeneticVariation |
| umls:C0027022 | Myeloproliferative Disorders | 30 | Biomarker, GeneticVariation |
| umls:C0007137 | Carcinoma, Squamous Cell | 14 | AlteredExpression, Biomarker |
| umls:C0220658 | PFEIFFER SYNDROME | 14 | Biomarker, GeneticVariation |
| umls:C0007131 | Carcinoma, Non-Small-Cell Lung | 14 | Biomarker |
| umls:C1458155 | Breast Neoplasms | 9 | AlteredExpression, Biomarker |
| umls:C0008925 | Cleft Palate | 6 | Biomarker, GeneticVariation |
| umls:C0017638 | Glioma | 5 | Biomarker |
| umls:C0008924 | Cleft Lip | 4 | Biomarker, GeneticVariation |
| umls:C0004114 | Astrocytoma | 4 | Biomarker |
| umls:C0036341 | Schizophrenia | 3 | Biomarker, GeneticVariation |
| umls:C0149925 | Small Cell Lung Carcinoma | 3 | Biomarker |
| umls:C1563720 | HYPOGONADOTROPIC HYPOGONADISM 2 WITH OR WITHOUT ANOSMIA | 2 | Biomarker, GeneticVariation |
| umls:C0432283 | Osteoglophonic dwarfism | 1 | Biomarker, GeneticVariation |
| umls:C0432122 | Trigonocephaly, Nonsyndromic | 1 | Biomarker, GeneticVariation |
| umls:C1845146 | Holoprosencephaly, Ectrodactyly, and Bilateral Cleft Lip/Palate | 1 | Biomarker, GeneticVariation |
| umls:C0376634 | Craniofacial Abnormalities | 1 | Biomarker |
| umls:C0011581 | Depressive Disorder | 1 | Biomarker |
| umls:C0024121 | Lung Neoplasms | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for FGFR1 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Approved | DB00039 | Palifermin | Biotech |  |
| Approved|investigational | DB00398 | Sorafenib | Small molecule |  |
| Experimental | DB02058 | SU4984 | Small molecule |  |
| Investigational | DB05014 | XL999 | Small molecule |  |
| Experimental | DB07525 | 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine | Small molecule |  |
| Experimental | DB07840 | (E)-[4-(3,5-difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol | Small molecule |  |
| Experimental | DB08577 | 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE | Small molecule |  |
| Approved | DB08896 | Regorafenib | Small molecule |  |
| Approved | DB08901 | Ponatinib | Small molecule |  |
| Approved | DB09078 | Lenvatinib | Small molecule |  |
| Approved | DB09079 | Nintedanib | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of FGFR1 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | UAP | 1,4-DIDEOXY-5-DEHYDRO-O2-SULFO-GLUCURONIC ACID | 1fq9 | D | D218 | SU1 | SU5402 | 1fgi | A | I545 L630 | SU1 | SU5402 | 1fgi | B | I545 L630 | C4F | 3-(3-METHOXYBENZYL)-1H-PYRROLO[2,3-B]PYRIDINE | 3c4f | A | I545 L630 | C4F | 3-(3-METHOXYBENZYL)-1H-PYRROLO[2,3-B]PYRIDINE | 3c4f | B | I545 L630 | GQL | (E)-[4-(3,5-DIFLUOROPHENYL)-3H-PYRROLO[2,3-B]PYRIDIN-3-YLIDENE](3-METHOXYPHENYL)METHANOL | 3gql | A | I545 L630 | GQL | (E)-[4-(3,5-DIFLUOROPHENYL)-3H-PYRROLO[2,3-B]PYRIDIN-3-YLIDENE](3-METHOXYPHENYL)METHANOL | 3gql | B | I545 L630 | GQL | (E)-[4-(3,5-DIFLUOROPHENYL)-3H-PYRROLO[2,3-B]PYRIDIN-3-YLIDENE](3-METHOXYPHENYL)METHANOL | 3gql | C | I545 L630 | VM1 | 5-THIOPHEN-2-YLPYRIDINE-3-CARBOXYLIC ACID | 3js2 | A | I545 L630 | 3RH | (6S)-6-PHENYL-5,6-DIHYDROBENZO[H]QUINAZOLIN-2-AMINE | 3rhx | B | I545 L630 | 3RH | (6S)-6-PHENYL-5,6-DIHYDROBENZO[H]QUINAZOLIN-2-AMINE | 3rhx | A | I545 L630 | 07J | BGJ398 | 3-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-1-(6-{[4-(4- ETHYLPIPERAZIN-1-YL)PHENYL]AMINO}PYRIMIDIN-4-YL)-1- METHYLUREA | 3tt0 | A | I545 L630 | 07J | BGJ398 | 3-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-1-(6-{[4-(4- ETHYLPIPERAZIN-1-YL)PHENYL]AMINO}PYRIMIDIN-4-YL)-1- METHYLUREA | 3tt0 | B | I545 L630 | 2K5 | N~4~-{5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3- YL}-N~2~-[(3-METHYL-1,2-OXAZOL-5-YL)METHYL]PYRIMIDINE- 2,4-DIAMINE | 4nk9 | A | I545 L630 | 2K5 | N~4~-{5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3- YL}-N~2~-[(3-METHYL-1,2-OXAZOL-5-YL)METHYL]PYRIMIDINE- 2,4-DIAMINE | 4nk9 | B | I545 L630 | 2K7 | N~4~-{3-[2-(3,4-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5- YL}-N~2~-[(3-METHYL-1,2-OXAZOL-5-YL)METHYL]PYRIMIDINE- 2,4-DIAMINE | 4nka | A | I545 L630 | 2K7 | N~4~-{3-[2-(3,4-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5- YL}-N~2~-[(3-METHYL-1,2-OXAZOL-5-YL)METHYL]PYRIMIDINE- 2,4-DIAMINE | 4nka | B | I545 L630 | LWJ | [5-AMINO-1-(2-METHYL-1H-BENZIMIDAZOL-6-YL)-1H-PYRAZOL- 4-YL](1H-INDOL-2-YL)METHANONE | 3wj6 | B | I545 L630 | SU2 | 3-[4-(1-FORMYLPIPERAZIN-4-YL)-BENZYLIDENYL]-2-INDOLINONE | 1agw | A | I545 S565 L630 | SU2 | 3-[4-(1-FORMYLPIPERAZIN-4-YL)-BENZYLIDENYL]-2-INDOLINONE | 1agw | B | I545 S565 L630 | PD1 | PD173074 | 2fgi | A | I545 S565 L630 | PD1 | PD173074 | 2fgi | B | I545 S565 L630 | 0S9 | 5-BROMO-N~2~-[(3-METHYL-1,2-OXAZOL-5-YL)METHYL]-N~4~- [3-(2-PHENYLETHYL)-1H-PYRAZOL-5-YL]PYRIMIDINE-2,4- DIAMINE | 4f65 | B | I545 S565 L630 | LWJ | [5-AMINO-1-(2-METHYL-1H-BENZIMIDAZOL-6-YL)-1H-PYRAZOL- 4-YL](1H-INDOL-2-YL)METHANONE | 3wj6 | A | I545 S565 L630 | 66T | N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4- [(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE | 4wun | A | I545 S565 L630 | 66T | N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4- [(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE | 4wun | B | I545 S565 L630 | DOV | 1-AMINO-5-FLUORO-3-(6-(4-METHYLPIPERAZIN-1- YL)-1H-BENZO[D]IMIDAZOL-2-YL)QUINOLIN-2(1H)- ONE | 4uwz | A | I545 S565 L630 | DOV | 1-AMINO-5-FLUORO-3-(6-(4-METHYLPIPERAZIN-1- YL)-1H-BENZO[D]IMIDAZOL-2-YL)QUINOLIN-2(1H)- ONE | 4uwz | B | I545 S565 L630 | DOV | 1-AMINO-5-FLUORO-3-(6-(4-METHYLPIPERAZIN-1- YL)-1H-BENZO[D]IMIDAZOL-2-YL)QUINOLIN-2(1H)- ONE | 4ux0 | A | I545 S565 L630 | DOV | 1-AMINO-5-FLUORO-3-(6-(4-METHYLPIPERAZIN-1- YL)-1H-BENZO[D]IMIDAZOL-2-YL)QUINOLIN-2(1H)- ONE | 4ux0 | B | I545 S565 L630 | 38O | DOVITINIB | 4-AMINO-5-FLUORO-3-[5-(4-METHYLPIPERAZIN-1- YL)-1H-BENZIMIDAZOL-2-YL]QUINOLIN-2(1H)-ONE | 5am6 | A | I545 S565 L630 | 38O | DOVITINIB | 4-AMINO-5-FLUORO-3-[5-(4-METHYLPIPERAZIN-1- YL)-1H-BENZIMIDAZOL-2-YL]QUINOLIN-2(1H)-ONE | 5am6 | B | I545 S565 L630 | 38O | DOVITINIB | 4-AMINO-5-FLUORO-3-[5-(4-METHYLPIPERAZIN-1- YL)-1H-BENZIMIDAZOL-2-YL]QUINOLIN-2(1H)-ONE | 5am7 | A | I545 S565 L630 | 38O | DOVITINIB | 4-AMINO-5-FLUORO-3-[5-(4-METHYLPIPERAZIN-1- YL)-1H-BENZIMIDAZOL-2-YL]QUINOLIN-2(1H)-ONE | 5am7 | B | I545 S565 L630 | 66T | N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4- [(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE | 4rwj | A | I545 S565 L630 | 66T | N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4- [(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE | 4rwj | B | I545 S565 L630 | JVT | N-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H- INDAZOLE-3-CARBOXAMIDE | 4uwb | A | I545 S565 L630 | 4Y0 | 3,4-DIMETHOXY-N-(5-PHENYL-1H-PYRAZOL-3-YL) BENZAMIDE | 4uwc | A | I545 S565 L630 | 4Y0 | 3,4-DIMETHOXY-N-(5-PHENYL-1H-PYRAZOL-3-YL) BENZAMIDE | 4uwc | B | I545 S565 L630 | 66T | N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4- [(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE | 4rwk | A | I545 S565 N628 L630 | UAP | 1,4-DIDEOXY-5-DEHYDRO-O2-SULFO-GLUCURONIC ACID | 1fq9 | D | K172 | SGN | N,O6-DISULFO-GLUCOSAMINE | 1fq9 | D | K172 | VM1 | 5-THIOPHEN-2-YLPYRIDINE-3-CARBOXYLIC ACID | 3js2 | B | L630 | 2M2 | N~2~-[(3-METHYL-1,2-OXAZOL-5-YL)METHYL]-N~4~-[5-(2- PHENYLETHYL)-1H-PYRAZOL-3-YL]PYRIMIDINE-2,4-DIAMINE | 4nks | A | L630 | 2M2 | N~2~-[(3-METHYL-1,2-OXAZOL-5-YL)METHYL]-N~4~-[5-(2- PHENYLETHYL)-1H-PYRAZOL-3-YL]PYRIMIDINE-2,4-DIAMINE | 4nks | B | L630 | MG | MAGNESIUM(2+) | 3gqi | A | N628 | ACP | ADENOSINE 5'-[BETA,GAMMA-METHYLENE]TRIPHOSPHATE | 3gqi | A | N628 L630 | IDS | 2-O-SULFO-ALPHA-L-IDOPYRANURONIC ACID | 1fq9 | C | R209 | 0S7 | 5-BROMO-N~4~-(3-METHYL-1H-PYRAZOL-5-YL)-N~2~-[2- (PYRIDIN-3-YL)ETHYL]PYRIMIDINE-2,4-DIAMINE | 4f63 | A | S565 L630 | 0S8 | 5-BROMO-N~4~-[3-(3-METHOXYPROPYL)-1H-PYRAZOL-5-YL]- N~2~-[(3-METHYL-1,2-OXAZOL-5-YL)METHYL]PYRIMIDINE-2,4- DIAMINE | 4f64 | A | S565 L630 | 0S8 | 5-BROMO-N~4~-[3-(3-METHOXYPROPYL)-1H-PYRAZOL-5-YL]- N~2~-[(3-METHYL-1,2-OXAZOL-5-YL)METHYL]PYRIMIDINE-2,4- DIAMINE | 4f64 | B | S565 L630 | 0S9 | 5-BROMO-N~2~-[(3-METHYL-1,2-OXAZOL-5-YL)METHYL]-N~4~- [3-(2-PHENYLETHYL)-1H-PYRAZOL-5-YL]PYRIMIDINE-2,4- DIAMINE | 4f65 | A | S565 L630 | 66T | N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4- [(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE | 4rwk | B | S565 L630 | 3ZC | 6-({7-[(1-AMINOCYCLOPROPYL)METHOXY]-6-METHOXYQUINOLIN- 4-YL}OXY)-N-METHYLNAPHTHALENE-1-CARBOXAMIDE | 4rwl | B | S565 L630 | 4UT | 4-(4-ETHYLPIPERAZIN-1-YL)-N-[6-(3-METHOXYPHENYL)-2H- INDAZOL-3-YL]BENZAMIDE | 4zsa | A | S565 L630 | 4UT | 4-(4-ETHYLPIPERAZIN-1-YL)-N-[6-(3-METHOXYPHENYL)-2H- INDAZOL-3-YL]BENZAMIDE | 4zsa | B | S565 L630 | 0S7 | 5-BROMO-N~4~-(3-METHYL-1H-PYRAZOL-5-YL)-N~2~-[2- (PYRIDIN-3-YL)ETHYL]PYRIMIDINE-2,4-DIAMINE | 4f63 | B | S565 N628 L630 |
| Top |
| Conservation information for LBS of FGFR1 |
| Multiple alignments for P11362 in multiple species |
| LBS | AA sequence | # species | Species | A512 | RVTKVAVKMLK | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | A564 | VIVEYASKGNL | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | A640 | NVMKIADFGLA | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | D218 | WSIIMDSVVPS | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | D641 | VMKIADFGLAR | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | E531 | SDLISEMEMMK | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | E562 | LYVIVEYASKG | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | E571 | KGNLREYLQAR | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | F489 | LGEGCFGQVVL | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | F642 | MKIADFGLARD | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | G490 | GEGCFGQVVLA | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | G567 | EYASKGNLREY | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | H166 | MEKKLHAVPAA | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | I216 | ATWSIIMDSVV | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | I545 | KHKNIINLLGA | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | K160 | WTSPEKMEKKL | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | K160 | WTYPEKMEKKL | 1 | Gallus gallus | K163 | PEKMEKKLHAV | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | K172 | AVPAAKTVKFK | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | K175 | AAKTVKFKCPS | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | K177 | KTVKFKCPSSG | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | K177 | KTVKFKCPSGG | 1 | Gallus gallus | K207 | RIGGYKVRYAT | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | K514 | TKVAVKMLKSD | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | K566 | VEYASKGNLRE | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | L630 | AARNVLVTEDN | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | M535 | SEMEMMKMIGK | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | N568 | YASKGNLREYL | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | N628 | DLAARNVLVTE | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | R209 | GGYKVRYATWS | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | R627 | RDLAARNVLVT | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | S565 | IVEYASKGNLR | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | T173 | VPAAKTVKFKC | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | V492 | GCFGQVVLAEA | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | V559 | DGPLYVIVEYA | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | V561 | PLYVIVEYASK | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus | Y563 | YVIVEYASKGN | 4 | Homo sapiens, Gallus gallus, Rattus norvegicus, Mus musculus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |